---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179464"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:53.455724+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kalaris Q2 2025 net loss $11.4M; Phase 1 TH103 data expected Q4 2025

## Summary
- Net loss $11.4M ($0.61/shr) vs $5.7M ($4.26/shr) in Q2 2024; no revenue in either period.
- Cash $88.4M at June 30, 2025 (up from $1.6M at Dec 31, 2024) after AlloVir merger.
- R&D expenses $8.4M (up from $3.2M YoY) driven by Phase 1 clinical trial initiation.
- Enrolling nAMD patients in Phase 1 trial of anti-VEGF TH103; initial data expected Q4 2025.
- Hired Kristine Curtiss as SVP of Clinical; over 25 years ophthalmology experience.

## SEC filing metadata
- accession: 0001193125-25-179464
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/0001193125-25-179464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179464
- JSON: https://secwatch.observer/filing/0001193125-25-179464.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.